Treatment Decisions for Favorable Risk RCC

March 12, 2024

By Elizabeth Plimack, MD
Benjamin L. Maughan, MD, PharmD

Opinion

Video

The panel discusses long-term data showing more limited benefit of IO-IO therapy versus TKI regimens for favorable risk RCC patients and implications for their risk-adapted treatment approach.

EP: 1.Long Term Follow Up Data From Checkmate 214 on Nivolumab Plus Ipilimumab in First Line Clear Cell RCC

EP: 2.Subgroup Analysis from CLEAR Trial: Efficacy Outcomes by Baseline Tumor Size in Treatment of Metastatic Clear Cell RCC

EP: 3.Network Meta-Analysis Comparing Efficacy of Lenvatinib Plus Pembrolizumab to Other First Line Treatments for Metastatic Clear Cell RCC

EP: 4.Frontline Treatment Approaches for Advanced Clear Cell RCC

Now Viewing

EP: 5.Treatment Decisions for Favorable Risk RCC

EP: 6.Managing Immune-Related Toxicities with Frontline RCC Therapies

EP: 7.Treating Patients with RCC and Brain, Liver, or Bone Metastases

EP: 8.Frontline Therapy for Patients With Non-Clear Cell RCC

EP: 9.Non-Clear Cell RCC: Key Learnings and Future Research Directions

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Subscribe Now!